KYNB:NASDAQ
Kyntra Bio Inc
USDÂ 4,57
0,00%
(0,00) 1D
30 Okt., 15:00:01 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KYNB...
Mkt. cap
18,50Â m
Avg. vol.
23,00Â k
Volume
19,00
P/E ratio
0,10
52-wk high
USDÂ 9,70
52-wk low
USDÂ 4,32
EPS
USDÂ 45,30
Beta
1,05
Shares outstanding
4,05Â m
No. of employees
34
Mkt. cap
18,50Â m
Avg. vol.
23,00Â k
Volume
19,00
P/E ratio
0,10
52-wk high
USDÂ 9,70
52-wk low
USDÂ 4,32
EPS
USDÂ 45,30
Beta
1,05
Shares outstanding
4,05Â m
No. of employees
34
News stories
From web sources and news partners
www.marketscreener.com
·
18 minute gelede
Stellantis Chooses Amperity to Personalize Experiences: NYSE Content Update
Schaeffer's Investment Research
·
12 minute gelede
Stock Futures Signal Strong Start to November
TradingView
·
29 minute gelede
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Seeking Alpha
·
42 minute gelede
SPYM: S&P 500 Monthly Dashboard For November (NYSEARCA:SPYM)
Profile
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
About Kyntra Bio Inc
CEO-
Employees34
Founded01 Jan. 1993
HeadquartersSan Francisco, Kalifornië, Verenigde State van Amerika
Sector-
Websitekyntrabio.com